Literature DB >> 10916592

Selecting a decision model for economic evaluation: a case study and review.

J Karnon1, J Brown.   

Abstract

The increased use of modelling techniques as a methodological tool in the economic evaluation of health care technologies has, in the main, been limited to two approaches--decision trees and Markov chain models. The former are suited to modelling simple scenarios that occur over a short time period, whilst Markov chain models allow longer time periods to be modelled, in continuous time, where the timing of an event is uncertain. In the context of economic evaluation, a less well developed technique is discrete event simulation, which may allow even greater flexibility. Taking the economic evaluation of adjuvant therapies for breast cancer as an illustrative example, the process of building a decision tree, a Markov chain model, and a discrete event simulation model are described. The potential benefits and problems of each approach are discussed. The suitability of the modelling techniques to economic evaluations of health care programmes in general is then discussed. This section aims to illustrate the areas in which the alternative modelling methods may be most appropriately employed.

Entities:  

Mesh:

Year:  1998        PMID: 10916592     DOI: 10.1023/a:1019090401655

Source DB:  PubMed          Journal:  Health Care Manag Sci        ISSN: 1386-9620


  29 in total

1.  A computer simulation model for cost-effectiveness analysis of cardiovascular disease prevention.

Authors:  M Johannesson; J Hedbrant; B Jönsson
Journal:  Med Inform (Lond)       Date:  1991 Oct-Dec

2.  Use of a stochastic simulation model to identify an efficient protocol for ovarian cancer screening.

Authors:  N Urban; C Drescher; R Etzioni; C Colby
Journal:  Control Clin Trials       Date:  1997-06

3.  Modelling in economic evaluation: an unavoidable fact of life.

Authors:  M J Buxton; M F Drummond; B A Van Hout; R L Prince; T A Sheldon; T Szucs; M Vray
Journal:  Health Econ       Date:  1997 May-Jun       Impact factor: 3.046

4.  Simulation modeling and health-care decision making.

Authors:  R W Klein; R S Dittus; S D Roberts; J R Wilson
Journal:  Med Decis Making       Date:  1993 Oct-Dec       Impact factor: 2.583

5.  Toward a peer review process for medical decision analysis models.

Authors:  F A Sonnenberg; M S Roberts; J Tsevat; J B Wong; M Barry; D L Kent
Journal:  Med Care       Date:  1994-07       Impact factor: 2.983

6.  A simulation model of the cost of the incidence of IDDM in Spain.

Authors:  W M Hart; C Espinosa; J Rovira
Journal:  Diabetologia       Date:  1997-03       Impact factor: 10.122

7.  Cost-effectiveness of fracture prevention in established osteoporosis.

Authors:  B Jönsson; C Christiansen; O Johnell; J Hedbrandt
Journal:  Osteoporos Int       Date:  1995-03       Impact factor: 4.507

8.  Assessing the cost effectiveness of adjuvant therapies in early breast cancer using a decision analysis model.

Authors:  B E Hillner; T J Smith; C E Desch
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

9.  Cost-effectiveness of streptokinase for acute myocardial infarction: A combined meta-analysis and decision analysis of the effects of infarct location and of likelihood of infarction.

Authors:  A S Midgette; J B Wong; J R Beshansky; A Porath; C Fleming; S G Pauker
Journal:  Med Decis Making       Date:  1994 Apr-Jun       Impact factor: 2.583

10.  Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model.

Authors:  B E Hillner; T J Smith
Journal:  N Engl J Med       Date:  1991-01-17       Impact factor: 91.245

View more
  22 in total

1.  A proposed model for economic evaluations of major depressive disorder.

Authors:  Hossein Haji Ali Afzali; Jonathan Karnon; Jodi Gray
Journal:  Eur J Health Econ       Date:  2011-06-02

2.  Modeling the demand for long-term care services under uncertain information.

Authors:  Teresa Cardoso; Mónica Duarte Oliveira; Ana Barbosa-Póvoa; Stefan Nickel
Journal:  Health Care Manag Sci       Date:  2012-07-11

3.  Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode.

Authors:  Mattias Ekman; Peter Lindgren; Carolin Miltenburger; Genevieve Meier; Julie C Locklear; Mary Lou Chatterton
Journal:  Pharmacoeconomics       Date:  2012-06-01       Impact factor: 4.981

4.  Pharmacoeconomic analyses using discrete event simulation.

Authors:  J Jaime Caro
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 5.  A review of health care models for coronary heart disease interventions.

Authors:  K Cooper; S C Brailsford; R Davies; J Raftery
Journal:  Health Care Manag Sci       Date:  2006-11

6.  Cost-effectiveness of primary prevention of paediatric asthma: a decision-analytic model.

Authors:  G Feljandro P Ramos; Antoinette D I van Asselt; Sandra Kuiper; Johan L Severens; Tanja Maas; Edward Dompeling; J André Knottnerus; Onno C P van Schayck
Journal:  Eur J Health Econ       Date:  2013-10-06

Review 7.  [Modeling in value-based medicine].

Authors:  A S Neubauer; C Hirneiss; A Kampik
Journal:  Ophthalmologe       Date:  2010-03       Impact factor: 1.059

Review 8.  When to use discrete event simulation (DES) for the economic evaluation of health technologies? A review and critique of the costs and benefits of DES.

Authors:  Jonathan Karnon; Hossein Haji Ali Afzali
Journal:  Pharmacoeconomics       Date:  2014-06       Impact factor: 4.981

Review 9.  Decision-analytic modeling as a tool for selecting optimal therapy incorporating hematopoietic stem cell transplantation in patients with hematological malignancy.

Authors:  Shigeo Fuji; Arnon Nagler; Mohamad Mohty; Bipin Savani; Roni Shouval
Journal:  Bone Marrow Transplant       Date:  2020-01-13       Impact factor: 5.483

10.  Modelling approaches: the case of schizophrenia.

Authors:  Bart M S Heeg; Joep Damen; Erik Buskens; Sue Caleo; Frank de Charro; Ben A van Hout
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.